Spots Global Cancer Trial Database for carcinoma, ductal

Every month we try and update this database with for carcinoma, ductal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	NCT04660929	HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm...	CT-0508 Pembrolizumab	18 Years -	Carisma Therapeutics Inc
Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC	NCT00321048	Breast Neoplasm... Carcinoma, Duct... Adenocarcinoma	Active Breathin...	18 Years - 100 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	NCT04660929	HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm...	CT-0508 Pembrolizumab	18 Years -	Carisma Therapeutics Inc
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs	NCT04985357	Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin...		18 Years -	Travera Inc
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer	NCT00106002	Breast Cancer Breast Neoplasm... Carcinoma, Duct...	pemetrexed	18 Years -	Eli Lilly and Company
Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer	NCT00185744	Breast Cancer Carcinoma, Duct...	Intra-Operative... Lumpectomy Whole Breast Ra... Intracavitary B... Accelerated Ext... Stereotactic AP...	40 Years -	Stanford University
Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer	NCT00185744	Breast Cancer Carcinoma, Duct...	Intra-Operative... Lumpectomy Whole Breast Ra... Intracavitary B... Accelerated Ext... Stereotactic AP...	40 Years -	Stanford University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: